<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470908</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-112</org_study_id>
    <nct_id>NCT04470908</nct_id>
  </id_info>
  <brief_title>The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males</brief_title>
  <official_title>A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of the Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effect of the moderate cytochrome
      P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy
      males.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) from time zero to the time of the last quantifiable concentration (AUC0-t) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to infinity (AUC0-âˆž) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum observed plasma concentration (Tmax) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of zanubrutinib</measure>
    <time_frame>Days 1 and 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <condition>Male</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib + Rifabutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: zanubrutinib
Days 3 to 10: rifabutin
Day 11: zanubrutinib and rifabutin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Single oral dose of 320 mg</description>
    <arm_group_label>Zanubrutinib + Rifabutin</arm_group_label>
    <other_name>BGB-3111</other_name>
    <other_name>Brukinsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Oral dose of 300 mg once daily</description>
    <arm_group_label>Zanubrutinib + Rifabutin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males of any race, between 18 and 65 years of age, inclusive.

          2. Male participants in good health as determined by past medical history, physical
             examination, vital signs, ECG and laboratory tests at screening

          3. Must have a body mass index (BMI) between 18 and 32 kg/m2

        Key Exclusion Criteria:

          1. Participants with a clinically relevant history or presence of any clinically
             significant disease

          2. History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy,
             cholecystectomy, and hernia repair will be allowed)

          3. History of drug or alcohol abuse within 1 year prior to check-in

          4. Use or intended use of any nonprescription medications/products including vitamins,
             minerals, herbal/plant-derived preparations within 7 days prior to check-in

          5. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result and/or a
             positive human immunodeficiency virus (HIV) at screening

          6. Use of tobacco- or nicotine-containing products within 3 months prior to check-in

          7. Use or intended use of any prescription medications/products within 14 days prior to
             check-in

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Novotny, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Pharmokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

